Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1967 1
1982 1
1989 1
2000 1
2002 2
2003 2
2005 1
2006 1
2007 3
2008 1
2009 6
2010 2
2013 2
2014 6
2015 3
2016 2
2017 7
2018 8
2019 6
2020 7
2021 6
2022 10
2023 12
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

86 results

Results by year

Filters applied: . Clear all
Page 1
Rhino-orbital-cerebral Mucormycosis.
Niculae CM, Craciun L. Niculae CM, et al. Among authors: craciun l. N Engl J Med. 2024 Mar 21;390(12):e30. doi: 10.1056/NEJMicm2309352. Epub 2024 Mar 16. N Engl J Med. 2024. PMID: 38502066 No abstract available.
Functional Th1-oriented T follicular helper cells that infiltrate human breast cancer promote effective adaptive immunity.
Noël G, Fontsa ML, Garaud S, De Silva P, de Wind A, Van den Eynden GG, Salgado R, Boisson A, Locy H, Thomas N, Solinas C, Migliori E, Naveaux C, Duvillier H, Lucas S, Craciun L, Thielemans K, Larsimont D, Willard-Gallo K. Noël G, et al. Among authors: craciun l. J Clin Invest. 2021 Oct 1;131(19):e139905. doi: 10.1172/JCI139905. J Clin Invest. 2021. PMID: 34411002 Free PMC article.
Thyroid cancer under the scope of emerging technologies.
Tarabichi M, Demetter P, Craciun L, Maenhaut C, Detours V. Tarabichi M, et al. Among authors: craciun l. Mol Cell Endocrinol. 2022 Feb 5;541:111491. doi: 10.1016/j.mce.2021.111491. Epub 2021 Nov 2. Mol Cell Endocrinol. 2022. PMID: 34740746 Review.
Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial.
Buisseret L, Loirat D, Aftimos P, Maurer C, Punie K, Debien V, Kristanto P, Eiger D, Goncalves A, Ghiringhelli F, Taylor D, Clatot F, Van den Mooter T, Ferrero JM, Bonnefoi H, Canon JL, Duhoux FP, Mansi L, Poncin R, Barthélémy P, Isambert N, Denis Z, Catteau X, Salgado R, Agostinetto E, de Azambuja E, Rothé F, Craciun L, Venet D, Romano E, Stagg J, Paesmans M, Larsimont D, Sotiriou C, Ignatiadis M, Piccart-Gebhart M. Buisseret L, et al. Among authors: craciun l. Nat Commun. 2023 Nov 2;14(1):7018. doi: 10.1038/s41467-023-42744-y. Nat Commun. 2023. PMID: 37919269 Free PMC article. Clinical Trial.
First-in-human study of SBRT and adenosine pathway blockade to potentiate the benefit of immunochemotherapy in early-stage luminal B breast cancer: results of the safety run-in phase of the Neo-CheckRay trial.
De Caluwe A, Romano E, Poortmans P, Gombos A, Agostinetto E, Marta GN, Denis Z, Drisis S, Vandekerkhove C, Desmet A, Philippson C, Craciun L, Veys I, Larsimont D, Paesmans M, Van Gestel D, Salgado R, Sotiriou C, Piccart-Gebhart M, Ignatiadis M, Buisseret L. De Caluwe A, et al. Among authors: craciun l. J Immunother Cancer. 2023 Dec 6;11(12):e007279. doi: 10.1136/jitc-2023-007279. J Immunother Cancer. 2023. PMID: 38056900 Free PMC article. Clinical Trial.
Nanopharmacology in translational hematology and oncology.
Tomuleasa C, Braicu C, Irimie A, Craciun L, Berindan-Neagoe I. Tomuleasa C, et al. Among authors: craciun l. Int J Nanomedicine. 2014 Jul 22;9:3465-79. doi: 10.2147/IJN.S60488. eCollection 2014. Int J Nanomedicine. 2014. PMID: 25092977 Free PMC article. Review.
86 results